Sugammadex Administration in Pregnant Women: A Case Series of Maternal and Fetal Outcomes. Issue 2 (24th February 2021)

• Record Type: Journal Article
• Authors: Singh, Shubhangi; Klumpner, Thomas T.; Pancaro, Carlo; Rajala, Baskar; Kountanis, Joanna A.
• Is Part Of: A & A practice. Volume 15:Issue 2(2020)
• Page Start: e01407
• Publication Date: 2021-02-24
• Subjects: Analgesia -- Periodicals; Analgesia -- Case studies -- Periodicals; Anesthesiology -- Periodicals; Anesthesiology -- Case studies -- Periodicals; 617.9605
• DOI: 10.1213/XAA.0000000000001407
• Languages: English
• ISSNs: 2575-3126

Abstract

Abstract : Sugammadex, given its high affinity for amino-steroid neuromuscular blockers, offers rapid and reliable neuromuscular blockade reversal, making it a popular reversal agent. This characteristic can be very useful in pregnant women, where incomplete reversal can have poor maternal and fetal outcomes. However, its use antenatally in pregnancy is controversial given concerns for progesterone binding, a hormone that is crucial for maintenance of pregnancy. This case series presents obstetric and fetal outcomes in 25 pregnant women who received sugammadex during the antenatal period, thus highlighting the need for further research into the safety of sugammadex during pregnancy.